Search Within

Robert Motzer

Formats
  1. Journal Article (609)
  2. Meeting Abstract (578)
  3. Book Section (20)
  4. Review (13)
  5. Correspondence (7)
  6. Conference Paper (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (3)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1248)
  2. Genitourinary Oncology Service (1248)
  3. Solid Tumor Oncology Division (1248)
  4. Surgery (290)
  5. Urology (281)
  6. Survivorship Research (253)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (31)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Elsevier Science, Inc. (111)
  3. Oxford University Press (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (86)
  6. American Association for Cancer Research (58)

More Publishers

Results (1248)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma
    Meeting Abstract

    Tannir, N. M.; Motzer, R. J.; Agarwal, N.; Liu, P. Y.; Whiting, S. H.; O'Keeffe, B.; Tran, X.; Fiji, G. P.; Escudier, B.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC
    Meeting Abstract

    Ravaud, A.; George, D. J.; Motzer, R. J.; Pantuck, A. J.; Staehler, M. D.; Serfass, L.; Krishnaswami, S.; Casey, M.; DeAnnuntis, L. L.; Lechuga, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial
    Meeting Abstract

    Patel, A.; Ravaud, A.; Motzer, R. J.; Pantuck, A. J.; Staehler, M. D.; Escudier, B.; Martini, J. F.; Krishnaswami, S.; Casey, M.; Lechuga, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    Meeting Abstract

    McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results
    Meeting Abstract

    Lee, C. H.; Makker, V.; Rasco, D. W.; Taylor, M. H.; Stepan, D. E.; Shumaker, R. C.; Schmidt, E. V.; Guo, M.; Dutcus, C. E.; Motzer, R. J.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant
    Meeting Abstract

    Ged, Y.; Knezevic, A.; Chen, Y.; Redzematovic, A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts)
    Meeting Abstract

    Funt, S.; McHugh, D. J.; Tsai, S.; O'Donnell, D.; Knezevic, A.; Patil, S.; Silber, D.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Escudier, B.; Motzer, R. J.; Rini, B. I.; Powles, T.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Gurney, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial
    Meeting Abstract

    Cella, D.; Grünwald, V.; Escudier, B.; Hammers, H. J.; George, S.; Nathan, P.; Grimm, M. O.; Rini, B. I.; Doan, J.; Ivanescu, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save